Cargando…

AXL inhibition improves BRAF-targeted treatment in melanoma

More than half of metastatic melanoma patients receiving standard therapy fail to achieve a long-term survival due to primary and/or acquired resistance. Tumor cell ability to switch from epithelial to a more aggressive mesenchymal phenotype, attributed with AXL(high) molecular profile in melanoma,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nyakas, Marta, Fleten, Karianne Giller, Haugen, Mads Haugland, Engedal, Nikolai, Sveen, Christina, Farstad, Inger Nina, Flørenes, Vivi Ann, Prasmickaite, Lina, Mælandsmo, Gunhild Mari, Seip, Kotryna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8948193/ https://www.ncbi.nlm.nih.gov/pubmed/35332208 http://dx.doi.org/10.1038/s41598-022-09078-z

Ejemplares similares

Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors
por: Seip, Kotryna, et al.
Publicado: (2016)

Soluble AXL as a marker of disease progression and survival in melanoma
por: Flem-Karlsen, Karine, et al.
Publicado: (2020)

hvTRA, a novel TRAIL receptor agonist, induces apoptosis and sustained growth retardation in melanoma
por: Fleten, Karianne G, et al.
Publicado: (2016)

A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases()
por: Flørenes, Vivi Ann, et al.
Publicado: (2019)

Dacarbazine and the Agonistic TRAIL Receptor-2 Antibody Lexatumumab Induce Synergistic Anticancer Effects in Melanoma
por: Engesæter, Birgit, et al.
Publicado: (2012)

Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma
por: Magnussen, Gry Irene, et al.
Publicado: (2015)

Detection of phenotype‐specific therapeutic vulnerabilities in breast cells using a CRISPR loss‐of‐function screen
por: Barkovskaya, Anna, et al.
Publicado: (2021)

Oncolytic peptides DTT-205 and DTT-304 induce complete regression and protective immune response in experimental murine colorectal cancer
por: Fleten, Karianne Giller, et al.
Publicado: (2021)

O-GlcNAc Transferase Inhibition Differentially Affects Breast Cancer Subtypes
por: Barkovskaya, Anna, et al.
Publicado: (2019)

miR-101-5p Acts as a Tumor Suppressor in HER2-Positive Breast Cancer Cells and Improves Targeted Therapy
por: Normann, Lisa Svartdal, et al.
Publicado: (2022)

Inhibition of O-GlcNAc transferase activates tumor-suppressor gene expression in tamoxifen-resistant breast cancer cells
por: Barkovskaya, Anna, et al.
Publicado: (2020)

Breast cancer patient-derived explant cultures recapitulate in vivo drug responses
por: Pettersen, Solveig, et al.
Publicado: (2023)

MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro
por: Normann, Lisa Svartdal, et al.
Publicado: (2021)

Cytoplasmic BRMS1 expression in malignant melanoma is associated with increased disease-free survival
por: Slipicevic, Ana, et al.
Publicado: (2012)

p38 MAPK activation through B7-H3-mediated DUSP10 repression promotes chemoresistance
por: Flem-Karlsen, Karine, et al.
Publicado: (2019)

Basal‐like breast cancer engages tumor‐supportive macrophages via secreted factors induced by extracellular S100A4
por: Prasmickaite, Lina, et al.
Publicado: (2018)

High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer
por: Normann, Lisa Svartdal, et al.
Publicado: (2023)

Melanoma brain colonization involves the emergence of a brain-adaptive phenotype
por: Nygaard, Vigdis, et al.
Publicado: (2014)

Aldehyde Dehydrogenase (ALDH) Activity Does Not Select for Cells with Enhanced Aggressive Properties in Malignant Melanoma
por: Prasmickaite, Lina, et al.
Publicado: (2010)

Protein Kinase C Isozymes Associated With Relapse Free Survival in Non-Small Cell Lung Cancer Patients
por: Halvorsen, Ann Rita, et al.
Publicado: (2020)

Construction of a plasmid coding for green fluorescent protein tagged cathepsin L and data on expression in colorectal carcinoma cells
por: Tamhane, Tripti, et al.
Publicado: (2015)

BRAF and AXL oncogenes drive RIPK3 expression loss in cancer
por: Najafov, Ayaz, et al.
Publicado: (2018)

Differential In Vivo Tumorigenicity of Distinct Subpopulations from a Luminal-Like Breast Cancer Xenograft
por: Skrbo, Nirma, et al.
Publicado: (2014)

Nuclear Legumain Activity in Colorectal Cancer
por: Haugen, Mads H., et al.
Publicado: (2013)

Correction: Nuclear Legumain Activity in Colorectal Cancer
por: Haugen, Mads H., et al.
Publicado: (2013)

A combined experimental-computational approach uncovers a role for the Golgi matrix protein Giantin in breast cancer progression
por: Ghannoum, Salim, et al.
Publicado: (2023)

Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma
por: Saelen, Marie Grøn, et al.
Publicado: (2012)

Experimental Treatment of Mucinous Peritoneal Metastases Using Patient-Derived Xenograft Models
por: Fleten, Karianne Giller, et al.
Publicado: (2020)

Alginate Microsphere Encapsulation of Drug-Loaded Nanoparticles: A Novel Strategy for Intraperitoneal Drug Delivery
por: Fleten, Karianne Giller, et al.
Publicado: (2022)

Cystatin E/M suppresses legumain activity and invasion of human melanoma
por: Briggs, Jon J, et al.
Publicado: (2010)

Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy
por: Dillard, Pierre, et al.
Publicado: (2021)

The fatty acid binding protein 7 (FABP7) is involved in proliferation and invasion of melanoma cells
por: Slipicevic, Ana, et al.
Publicado: (2008)

Liver X receptors induce antiproliferative effects in basal‐like breast cancer
por: Haugen, Mads Haugland, et al.
Publicado: (2023)

EMMPRIN is associated with S100A4 and predicts patient outcome in colorectal cancer
por: Boye, K, et al.
Publicado: (2012)

Giving AXL the axe: targeting AXL in human malignancy
por: Gay, Carl M, et al.
Publicado: (2017)

Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer
por: Grinde, Maria T., et al.
Publicado: (2019)

Sensitization of interferon-γ induced apoptosis in human osteosarcoma cells by extracellular S100A4
por: Pedersen, Kjetil Boye, et al.
Publicado: (2004)

A PRRX1 Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver Metastases
por: Nygaard, Vigdis, et al.
Publicado: (2023)

Targeting AXL in NSCLC
por: Zaman, Aubhishek, et al.
Publicado: (2021)

A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITF(high)/AXL(low) melanoma
por: Smith, Michael P., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ls5i394rfesde2ljp2k55imqdn